Table 1.

Key Design Characteristics of Current Bioresorbable Scaffold Technologies.

Device (Manufacturer) Drug Backbone Material Strut Thickness (μm) Bioresorption Time (months) EU CE Mark FDA Approval
ABSORB GT1 BRS (Abbott) Everolimus PLLA 156 24–36 Jan 2011 July 2016*
DESolve (Elixir Medical) Novalimus PLLA 150 24–36 May 2014 No
ART Pure (Arterial Remodelling Technologies) Drug-free PDLLA 170 12–24 May 2015 No
MeRes 100 (Meril Life Sciences) Sirolimus PLLA 180 24 August 2019 No
FORTITUDE (Amaranth Medical) Sirolimus PLLA 150 12–24 No No
APTITUDE (Amaranth Medical) Sirolimus PLLA 115 12–24 No No
MAGNITUDE (Amaranth Medical) Sirolimus PLLA 98 12–24 No No
DEFIANCE (Amaranth Medical) Sirolimus PLLA 85 12–24 No No
Mirage (Manli) Sirolimus PLLA 125–150 14 No No
NeoVas (Lepu Medical Technology) Sirolimus PLLA 180 36 No No
Firesorb (Shanghai MicroPort) Sirolimus PLLA 100–125 36 No No
Falcon (Abbott) Everolimus PLLA <100 No No
Fantom (REVA Medical) Sirolimus DAT 125 12 April 2017 No
Magmaris (Biotronik) Sirolimus Magnesium 120–150 12 June 2016 No
IBS (Lifetech Scientific) Sirolimus Iron 70 >12 No No
*US sales discontinued September 2017.

DAT, Desaminotyrosine polycarbonate; PDLLA, poly-D, L-lactic acid; PLLA, poly-L-lactic acid.

Modified with updated data from Jinnouchi H et al.6 with permission, ©2018 Springer Nature.

RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2020 April; 11(2): e0016. ISSN: 2076-9172
Published online 2020 April 29. doi: 10.5041/RMMJ.10402
Copyright: © 2020 Forrestal et al.